About usOur ApproachOur PipelinePatientsInvestorsCareers

You are leaving Spyre

If you would like to proceed, click the link to continue.
https://twitter.com/

Go back
Continue
Spyre is not responsible for content on external websites.
Please review their Privacy Policy.
Back to People
Michael Henderson

Michael Henderson

Dr. Michael Henderson was most recently the CEO of Apogee Therapeutics (acquired by AbbVie in September 2026). He is an experienced biotechnology executive with expertise in business leadership, drug development, and commercial strategy, having overseen the creation of multiple companies, launched a significant number of drug development programs, and led teams to two FDA approvals, to date.

Prior to Apogee, Dr. Henderson served as Chief Business Officer of BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, where he was responsible for furthering the overarching strategy of BridgeBio, identifying and investing in new technologies, and running business development and operations. Dr. Henderson also served in leadership positions for several prominent subsidiary companies of BridgeBio.

Prior to BridgeBio, Dr. Henderson worked at McKinsey & Company, before which he co-founded PellePharm, Inc., a biotechnology company. Dr. Henderson received his B.A. in global health from Harvard University and his M.D. from Stanford University.